-
ILCA 2023 | VETC Evaluation Predicts Clinical Benefit of Anti-Angiogenic Treatment in Advanced HCC Patients
Hepatocellular carcinoma (HCC) is a highly malignant tumor, and one of its main characteristics is its rich vascular supply. Therefore, anti-angiogenic drugs have become one of the most important choices in the systematic treatment of HCC. In recent years, as research on HCC has deepened, researchers have discovered a unique vascular pattern in HCC tissue.…
-
Dr. Nathalie Ganne-Carrié: Exploration and Clinical Practice of Biomarkers for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide. Although the prognosis for HCC patients is generally poor, if diagnosed early, the 5-year survival rate can exceed 70%. Currently, the diagnosis of HCC without pathological evidence mainly relies on analyzing serum alpha-fetoprotein (AFP) levels and radiological diagnosis. Therefore, exploring early diagnostic biomarkers for…
-
Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1…
-
ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer
Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered…
-
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer
Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer,…
-
ILCA 2023 | Dynamic Changes in Circulating Tumor DNA Assist in Guiding and Evaluating Clinical Treatment of Liver Cancer
Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered…
-
Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1…
-
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer
Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer,…
Connecting Medical Expertise through Media